BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21519830)

  • 1. Enhanced anti-tumor immunity by superantigen-pulsed dendritic cells.
    Kato M; Nakamura Y; Suda T; Ozawa Y; Inui N; Seo N; Nagata T; Koide Y; Kalinski P; Nakamura H; Chida K
    Cancer Immunol Immunother; 2011 Jul; 60(7):1029-38. PubMed ID: 21519830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic anti-tumor response induced with epitope-pulsed fibroblasts genetically engineered for B7.1 expression and IFN-gamma secretion.
    Kim TS; Chung SW; Kim SH; Kang SN; Kang BY
    Int J Cancer; 2000 Aug; 87(3):427-33. PubMed ID: 10897050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
    Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
    J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new dynamic model of CD8+ T effector cell responses via CD4+ T helper-antigen-presenting cells.
    Xiang J; Huang H; Liu Y
    J Immunol; 2005 Jun; 174(12):7497-505. PubMed ID: 15944248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycogen Synthase Kinase-3β (GSK-3β) Inhibition Enhances Dendritic Cell-based Cancer Vaccine Potency via Suppression of Interferon-γ-induced Indoleamine 2,3-Dioxygenase Expression.
    Noh KT; Son KH; Jung ID; Kang TH; Choi CH; Park YM
    J Biol Chem; 2015 May; 290(19):12394-402. PubMed ID: 25814664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes.
    Hao S; Bai O; Yuan J; Qureshi M; Xiang J
    Cell Mol Immunol; 2006 Jun; 3(3):205-11. PubMed ID: 16893501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity.
    Hao S; Bai O; Li F; Yuan J; Laferte S; Xiang J
    Immunology; 2007 Jan; 120(1):90-102. PubMed ID: 17073943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge.
    Krishnan L; Sad S; Patel GB; Sprott GD
    Cancer Res; 2003 May; 63(10):2526-34. PubMed ID: 12750276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A high-affinity T-helper epitope enhances peptide-pulsed dendritic cell-based vaccine.
    Li A; Xiong S; Lin Y; Liu R; Chu Y
    DNA Cell Biol; 2011 Nov; 30(11):883-92. PubMed ID: 21612399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4+ Th-APC with acquired peptide/MHC class I and II complexes stimulate type 1 helper CD4+ and central memory CD8+ T cell responses.
    Umeshappa CS; Huang H; Xie Y; Wei Y; Mulligan SJ; Deng Y; Xiang J
    J Immunol; 2009 Jan; 182(1):193-206. PubMed ID: 19109150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of antitumor immunity using bone marrow-generated dendritic cells.
    Porgador A; Snyder D; Gilboa E
    J Immunol; 1996 Apr; 156(8):2918-26. PubMed ID: 8609412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells.
    Sun JB; Eriksson K; Li BL; Lindblad M; Azem J; Holmgren J
    Clin Immunol; 2004 Jul; 112(1):35-44. PubMed ID: 15207780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.
    Ye Z; Ahmed KA; Hao S; Zhang X; Xie Y; Munegowda MA; Meng Q; Chibbar R; Xiang J
    Autoimmunity; 2008 Nov; 41(7):501-11. PubMed ID: 18855194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
    Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
    Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeated treatment with antibody-targeted superantigens strongly inhibits tumor growth.
    Rosendahl A; Kristensson K; Hansson J; Ohlsson L; Kalland T; Dohlsten M
    Int J Cancer; 1998 Apr; 76(2):274-83. PubMed ID: 9537591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon gamma stimulates cellular maturation of dendritic cell line DC2.4 leading to induction of efficient cytotoxic T cell responses and antitumor immunity.
    He T; Tang C; Xu S; Moyana T; Xiang J
    Cell Mol Immunol; 2007 Apr; 4(2):105-11. PubMed ID: 17484804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes.
    Porgador A; Gilboa E
    J Exp Med; 1995 Jul; 182(1):255-60. PubMed ID: 7540653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.
    Kikuchi T; Uehara S; Ariga H; Tokunaga T; Kariyone A; Tamura T; Takatsu K
    Immunology; 2006 Jan; 117(1):47-58. PubMed ID: 16423040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The distinct role of CD4+ and CD8+ T-cells during the anti-tumour effects of targeted superantigens.
    Litton MJ; Dohlsten M; Rosendahl A; Ohlsson L; Søgaard M; Andersson J; Andersson U
    Br J Cancer; 1999 Sep; 81(2):359-66. PubMed ID: 10496366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.